Further GSEA showed that tumor progression/recurrence-associated pathways (e.g., MCM, MAPK, Glycolysis, Wnt, Myc, and p53) were evidently enriched in the high-risk patients with HCC. Here, TP53 is linked to hepatocellular carcinoma.